Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
Glucagon Like Peptide-1 (GLP-1) Agonists report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Glucagon Like Peptide-1 (GLP-1) Agonists market is projected to reach US$ 21340 million in 2034, increasing from US$ 8816.2 million in 2022, with the CAGR of 13.3% during the period of 2024 to 2034. Demand from Hospital and Pharmacy are the major drivers for the industry.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Glucagon Like Peptide-1 (GLP-1) Agonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Hospital
Pharmacy
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Glucagon Like Peptide-1 (GLP-1) Agonists market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Glucagon Like Peptide-1 (GLP-1) Agonists, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Glucagon Like Peptide-1 (GLP-1) Agonists industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Glucagon Like Peptide-1 (GLP-1) Agonists in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Glucagon Like Peptide-1 (GLP-1) Agonists introduction, etc. Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Glucagon Like Peptide-1 (GLP-1) Agonists market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Glucagon Like Peptide-1 (GLP-1) Agonists report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Glucagon Like Peptide-1 (GLP-1) Agonists market is projected to reach US$ 21340 million in 2034, increasing from US$ 8816.2 million in 2022, with the CAGR of 13.3% during the period of 2024 to 2034. Demand from Hospital and Pharmacy are the major drivers for the industry.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Glucagon Like Peptide-1 (GLP-1) Agonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segment by Application
Hospital
Pharmacy
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Glucagon Like Peptide-1 (GLP-1) Agonists market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Glucagon Like Peptide-1 (GLP-1) Agonists, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Glucagon Like Peptide-1 (GLP-1) Agonists industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Glucagon Like Peptide-1 (GLP-1) Agonists in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Glucagon Like Peptide-1 (GLP-1) Agonists introduction, etc. Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Glucagon Like Peptide-1 (GLP-1) Agonists market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices